June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Optical coherence tomography risk factors for 3-year development of atrophy in eyes with age-related macular degeneration
Author Affiliations & Notes
  • Kazutaka Hirabayashi
    Doheny Eye Institute, Los Angeles, California, United States
    Hirabayashi Eye Clinic, Matsumoto, Nagano, Japan
  • Srinivas R Sadda
    Doheny Eye Institute, Los Angeles, California, United States
  • Hannah Yu
    Retina Consultants of Texas, Houston, Texas, United States
  • Kenneth Marion
    Doheny Eye Institute, Los Angeles, California, United States
  • Charles Clifton Wykoff
    Retina Consultants of Texas, Houston, Texas, United States
  • Footnotes
    Commercial Relationships   Kazutaka Hirabayashi None; Srinivas Sadda Amgen, Allergan, Genentech/Roche, Iveric, Oxurion, Novartis, Regeneron, Bayer, 4DMT, Centervue, Heidelberg, Optos, Merck, Apellis, Astellas, Code C (Consultant/Contractor), Carl Zeiss Meditec, Nidek, Code R (Recipient), Nidek, Topcon, Heidelberg, Carl Zeiss Meditec, Optos, Centervue, Code R (Recipient); Hannah Yu None; Kenneth Marion None; Charles Wykoff Apellis, Genentech/Roche, Iveric Bio, Novartis, NGM, Gyroscope, Janssen, Code C (Consultant/Contractor)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 2532 – A0101. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kazutaka Hirabayashi, Srinivas R Sadda, Hannah Yu, Kenneth Marion, Charles Clifton Wykoff; Optical coherence tomography risk factors for 3-year development of atrophy in eyes with age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2022;63(7):2532 – A0101.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To determine the frequency of various optical coherence tomography (OCT) biomarkers of intermediate age-related macular degeneration (int-AMD) and their relationship with the development of complete retinal pigment epithelium and outer retinal atrophy(cRORA) after 3 or more years.

Methods : This retrospective study enrolled 1118 eyes of 765 consecutive patients with int-AMD and at least 12 months of follow-up (including OCT) who were evaluated between October 2016 and October 2020 in Retina Consultant of Houston eye clinics. 250 of these eyes had 36-48 months of follow-up and were included in this analysis. Spectralis OCT 49 slice volume scans at baseline were evaluated for biomarkers including a high central drusen volume (define as ≥ 0.03mm3), intraretinal hyperreflective foci (IHRF), subretinal drusenoid deposits (SDD), hyporeflective drusen cores (hDC), incomplete RORA (iRORA), and a thin or thick double layer sign (DLS). Demographic and systemic factors at baseline were also collected. The presence of cRORA was assessed at the final visit between 36 and 48 months. Odds ratios for the baseline features for development of cRORA were assessed using logistic regression and generalized estimating equations.

Results : The frequency of the various OCT biomarkers in this int-AMD cohort is shown in Table 1. Several baseline features were associated with a significantly higher risk for development of cRORA at 3 years including iRORA, IHRF, SDD, hDC, and a thin DLS. (Table 2). Interestingly, hypertension was associated with a significantly lower risk.

Conclusions : Several OCT biomarkers are associated with an increased risk for development of cRORA over three years. These biomarkers may be useful for prognostication and for selecting patients for enrollment into future early intervention clinical trials for AMD.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×